** Sleep apnea device maker Inspire Medical Systems' shares INSP.N fall 2.9% to $175.72 in morning trade
** Co late on Monday reported Q4 adj EPS of $1.15, above Wall Street est of 73 cents - data compiled by LSEG
** INSP said they have "made steady progress" toward the full launch of sleep apnea device Inspire V during Q4
** Wells Fargo says the launch is slower than expected due to hurdles at its U.S and Mexico manufacturing plants
** Scaling up production on a new U.S. line takes time, as management aims to minimize disruption to production of the older device Inspire IV while producing Inspire V, brokerage says
** Brokerage says a civil investigation by the U.S. justice department related to allegations of false information about co's devices submitted to the agency might hurt the stock
** Brokerages Truist, Morgan Stanley and Wells Fargo cut their PTs on INSP
** Stock was down 1.3% in 2024
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.